Cognition Therapeutics (CGTX) Competitors

Cognition Therapeutics logo
$0.60 -0.03 (-4.75%)
Closing price 04:00 PM Eastern
Extended Trading
$0.62 +0.02 (+2.67%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CGTX vs. AMRN, BIOA, LFCR, VNDA, and DRUG

Should you buy Cognition Therapeutics stock or one of its competitors? Cognition Therapeutics's main competitors and comparable companies include Amarin (AMRN), BioAge Labs (BIOA), Lifecore Biomedical (LFCR), Vanda Pharmaceuticals (VNDA), and Bright Minds Biosciences (DRUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cognition Therapeutics compare to Amarin?

Cognition Therapeutics (NASDAQ:CGTX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Cognition Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -10.87%. Amarin's return on equity of -0.52% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -50.57% -40.42%
Amarin -10.87%-0.52%-0.36%

Cognition Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 7 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Cognition Therapeutics and 4 mentions for Amarin. Cognition Therapeutics' average media sentiment score of 0.97 beat Amarin's score of 0.67 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amarin
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 429.18%. Amarin has a consensus target price of $13.00, suggesting a potential upside of 15.35%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cognition Therapeutics is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

Cognition Therapeutics has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A
Amarin$213.65M1.11-$38.80M-$0.96N/A

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cognition Therapeutics beats Amarin on 11 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to BioAge Labs?

Cognition Therapeutics (NASDAQ:CGTX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Cognition Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Cognition Therapeutics has higher earnings, but lower revenue than BioAge Labs. Cognition Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A
BioAge Labs$8.99M26.07-$80.61M-$2.55N/A

Cognition Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -1,253.60%. BioAge Labs' return on equity of -31.42% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -50.57% -40.42%
BioAge Labs -1,253.60%-31.42%-29.59%

In the previous week, Cognition Therapeutics had 9 more articles in the media than BioAge Labs. MarketBeat recorded 11 mentions for Cognition Therapeutics and 2 mentions for BioAge Labs. Cognition Therapeutics' average media sentiment score of 0.97 beat BioAge Labs' score of 0.45 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 429.18%. BioAge Labs has a consensus target price of $33.00, suggesting a potential upside of 547.06%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Cognition Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

Cognition Therapeutics and BioAge Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Lifecore Biomedical?

Cognition Therapeutics (NASDAQ:CGTX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cognition Therapeutics currently has a consensus target price of $3.33, indicating a potential upside of 429.18%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 1.72%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Lifecore Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Lifecore Biomedical
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

Cognition Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -56.80%. Lifecore Biomedical's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -50.57% -40.42%
Lifecore Biomedical -56.80%N/A -29.53%

Cognition Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 9 more articles in the media than Lifecore Biomedical. MarketBeat recorded 11 mentions for Cognition Therapeutics and 2 mentions for Lifecore Biomedical. Cognition Therapeutics' average media sentiment score of 0.97 beat Lifecore Biomedical's score of 0.60 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lifecore Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cognition Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A
Lifecore Biomedical$128.87M1.88-$70.51M-$1.86N/A

Summary

Cognition Therapeutics beats Lifecore Biomedical on 9 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Cognition Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -119.87%. Cognition Therapeutics' return on equity of -50.57% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vanda Pharmaceuticals-119.87% -62.70% -37.53%
Cognition Therapeutics N/A -50.57%-40.42%

In the previous week, Cognition Therapeutics had 9 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 11 mentions for Cognition Therapeutics and 2 mentions for Vanda Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.97 beat Vanda Pharmaceuticals' score of 0.85 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vanda Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cognition Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cognition Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$216.10M1.07-$220.47M-$4.62N/A
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vanda Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Vanda Pharmaceuticals currently has a consensus target price of $13.50, suggesting a potential upside of 254.33%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 429.18%. Given Cognition Therapeutics' higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Cognition Therapeutics beats Vanda Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Bright Minds Biosciences presently has a consensus target price of $126.29, indicating a potential upside of 515.73%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 429.18%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Bright Minds Biosciences is more favorable than Cognition Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.92
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.11, meaning that its share price is 611% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market.

Bright Minds Biosciences' return on equity of -12.46% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bright Minds BiosciencesN/A -12.46% -12.30%
Cognition Therapeutics N/A -50.57%-40.42%

In the previous week, Cognition Therapeutics had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 11 mentions for Cognition Therapeutics and 2 mentions for Bright Minds Biosciences. Cognition Therapeutics' average media sentiment score of 0.97 beat Bright Minds Biosciences' score of 0.93 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bright Minds Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cognition Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright Minds BiosciencesN/AN/A-$8.74M-$2.08N/A
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A

Summary

Bright Minds Biosciences beats Cognition Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGTX vs. The Competition

MetricCognition TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$57.06M$13.38B$7.59B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio-4.0028.1833.6629.92
Price / SalesN/A7.028.325.64
Price / CashN/A15.6321.0121.90
Price / Book1.945.394.443.72
Net Income-$23.49M$2.88B$3.50B$393.72M
7 Day Performance-11.41%-5.22%-6.53%-6.06%
1 Month Performance-17.79%-4.78%-4.92%-7.39%
1 Year Performance-60.53%-7.33%-1.72%-7.50%

Cognition Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGTX
Cognition Therapeutics
1.975 of 5 stars
$0.60
-4.7%
$3.33
+455.6%
-58.6%$57.06MN/AN/A14
AMRN
Amarin
1.6685 of 5 stars
$11.61
+0.3%
$13.00
+12.0%
-29.7%$245.24M$213.65MN/A80
BIOA
BioAge Labs
2.7143 of 5 stars
$5.34
-3.6%
$33.00
+518.0%
-38.6%$245.09M$10.36MN/A62
LFCR
Lifecore Biomedical
1.3917 of 5 stars
$6.36
-0.6%
$6.50
+2.2%
-19.1%$241.08M$128.87MN/A382
VNDA
Vanda Pharmaceuticals
3.8428 of 5 stars
$3.82
+6.4%
$13.50
+253.4%
-13.4%$231M$216.10MN/A533

Related Companies and Tools


This page (NASDAQ:CGTX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners